Market Cap 290.76M
Revenue (ttm) 22.27M
Net Income (ttm) -40.47M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -181.72%
Debt to Equity Ratio 0.00
Volume 638,100
Avg Vol 1,987,194
Day's Range N/A - N/A
Shares Out 45.72M
Stochastic %K 62%
Beta 0.73
Analysts Strong Sell
Price Target $20.60

Company Profile

Capricor Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of transformative cell and exosome-based therapeutics for treating duchenne muscular dystrophy (DMD) and other diseases with unmet medical needs in the United States. Its lead product candidate is the Deramiocel, an allogeneic cardiosphere-derived cells, which is in phase 3 clinical trial for the treatment of DMD. The company also develops Exosome protein-based vaccine, which is in preclinical trial t...

Industry: Biotechnology
Sector: Healthcare
Phone: 858 727 1755
Address:
10865 Road to the Cure, Suite 150, San Diego, United States
NoSwagger
NoSwagger Sep. 14 at 9:09 PM
$CAPR So it is my opinion that "It is a standard/common practice for biotechnology and pharmaceutical companies to register a shelf offering with the SEC before their PDUFA (Linda says it in 1 word) drug approval date. This strategy provides significant financial flexibility and is done to prepare for a positive or negative outcome from the FDA.". Let's say they prescheduled this, why not cancel it? Especially, with all the recent goings-on. Or is there something bigger happening? And this move offers some insight into that possibility?
1 · Reply
patatechaude
patatechaude Sep. 14 at 8:21 PM
$CAPR Never forget that Elevidys is now something that most DMD parents would like to see replaced by Deramiocel. Prasad would like to replace it as well. Hang tight.
1 · Reply
graywolf
graywolf Sep. 14 at 8:19 PM
$CAPR Companies do not operate around option expiration dates.
0 · Reply
patatechaude
patatechaude Sep. 14 at 8:12 PM
$CAPR The little army of Martin trolls has been busy on this board lately. I wonder why…
1 · Reply
Paradise27
Paradise27 Sep. 14 at 7:33 PM
$CAPR All that matters is HOPE 3 data. Minutes PR from Capricor, which could be next week or a month from now will confirm that HOPE 3 is required for a Class 2 BLA resubmission. Weak sheep on this thread worried about what day minutes will come out need to sell and move on. HOPE 3 will be out by November, resubmission by end of year. If HOPE 3 delivers FDA will expedite approval well before new PDUFA date which will be set for next Summer. I expect approval April/May timeframe. Those are the events that matter.
1 · Reply
ripztrip
ripztrip Sep. 14 at 6:35 PM
0 · Reply
ripztrip
ripztrip Sep. 14 at 6:32 PM
0 · Reply
ODLH
ODLH Sep. 14 at 6:25 PM
$CAPR We won’t see any positive PRs before the OE, I believe so.
0 · Reply
FriendsOfCapricor
FriendsOfCapricor Sep. 14 at 5:49 PM
0 · Reply
LuckyRonin1994
LuckyRonin1994 Sep. 14 at 5:32 PM
$CAPR I really hope PR comes with good news tomorrow, latest Tuesday… otherwise people will slowly loose trust in this stock.
1 · Reply
Latest News on CAPR
Capricor's Lead Duchenne Therapy Hits FDA Regulatory Roadblock

Jul 11, 2025, 9:03 AM EDT - 2 months ago

Capricor's Lead Duchenne Therapy Hits FDA Regulatory Roadblock


US FDA declines to approve Capricor's muscle disorder therapy

Jul 11, 2025, 6:36 AM EDT - 2 months ago

US FDA declines to approve Capricor's muscle disorder therapy


Why Is Capricor Therapeutics Stock Trading Lower On Monday?

Jun 23, 2025, 12:46 PM EDT - 2 months ago

Why Is Capricor Therapeutics Stock Trading Lower On Monday?


NoSwagger
NoSwagger Sep. 14 at 9:09 PM
$CAPR So it is my opinion that "It is a standard/common practice for biotechnology and pharmaceutical companies to register a shelf offering with the SEC before their PDUFA (Linda says it in 1 word) drug approval date. This strategy provides significant financial flexibility and is done to prepare for a positive or negative outcome from the FDA.". Let's say they prescheduled this, why not cancel it? Especially, with all the recent goings-on. Or is there something bigger happening? And this move offers some insight into that possibility?
1 · Reply
patatechaude
patatechaude Sep. 14 at 8:21 PM
$CAPR Never forget that Elevidys is now something that most DMD parents would like to see replaced by Deramiocel. Prasad would like to replace it as well. Hang tight.
1 · Reply
graywolf
graywolf Sep. 14 at 8:19 PM
$CAPR Companies do not operate around option expiration dates.
0 · Reply
patatechaude
patatechaude Sep. 14 at 8:12 PM
$CAPR The little army of Martin trolls has been busy on this board lately. I wonder why…
1 · Reply
Paradise27
Paradise27 Sep. 14 at 7:33 PM
$CAPR All that matters is HOPE 3 data. Minutes PR from Capricor, which could be next week or a month from now will confirm that HOPE 3 is required for a Class 2 BLA resubmission. Weak sheep on this thread worried about what day minutes will come out need to sell and move on. HOPE 3 will be out by November, resubmission by end of year. If HOPE 3 delivers FDA will expedite approval well before new PDUFA date which will be set for next Summer. I expect approval April/May timeframe. Those are the events that matter.
1 · Reply
ripztrip
ripztrip Sep. 14 at 6:35 PM
0 · Reply
ripztrip
ripztrip Sep. 14 at 6:32 PM
0 · Reply
ODLH
ODLH Sep. 14 at 6:25 PM
$CAPR We won’t see any positive PRs before the OE, I believe so.
0 · Reply
FriendsOfCapricor
FriendsOfCapricor Sep. 14 at 5:49 PM
0 · Reply
LuckyRonin1994
LuckyRonin1994 Sep. 14 at 5:32 PM
$CAPR I really hope PR comes with good news tomorrow, latest Tuesday… otherwise people will slowly loose trust in this stock.
1 · Reply
User123321
User123321 Sep. 14 at 5:11 PM
$CAPR No one asked you but you shouldn’t be scared.
1 · Reply
Skyhigh77
Skyhigh77 Sep. 14 at 5:09 PM
$CAPR all you fudsters that keep spewing about the S3.. this is not an offering.. it’s been out to eventually or if the company should need it in the future.. we hade one out in place last year in the spring which the company took the opportunity when the SP rocketed upwards and it’s going to be something of the same here.. they did this so if this takes time and we go into next year then they might need it if approved and they need to produce and ship Deramiocel and start selling the product… a company must be forward looking and take any scenario into consideration… they will not sell this as they used to via ATM… next week will be interesting… I think they got the Type A minutes on Friday and they will Pr it tomorrow pre market, we will see what it’ll bring
0 · Reply
Semafore
Semafore Sep. 14 at 4:23 PM
0 · Reply
Semafore
Semafore Sep. 14 at 4:23 PM
0 · Reply
Semafore
Semafore Sep. 14 at 4:22 PM
0 · Reply
User123321
User123321 Sep. 14 at 3:59 PM
$CAPR Perhaps the type A meeting minutes and any follow-up will provide more clarification. Hopefully they very much do otherwise what’s the actual point. I don’t agree with blind negativity but also disagree with echo chamber half truths and nonsense. This seems like a great risk reward although I’m in a few dollars higher but there’s two key words there. The reward outweighs the risk but right here you are risking $6.36. I’m hopeful that outcomes adjusted the reward is multiple times of that. Obviously at even $20 that’s well over a 200% return from here. I seek the truth and not bull💩 from both longs and shorts. However I will only wish the longs good luck.
1 · Reply
Semafore
Semafore Sep. 14 at 3:57 PM
$CAPR What exactly is the PATH to approval here and WHEN? @Asher77
3 · Reply
HamBoneXoXo
HamBoneXoXo Sep. 14 at 3:50 PM
$CAPR Even the benefit of the doubt suggests that FDA should act professionally and put forward a workable path for Capricor to unblind its large phase3 Hope3 trial to be evaluated on the strength of lvef and some strength of PUL.
1 · Reply
flash9875
flash9875 Sep. 14 at 3:25 PM
$CAPR A total takeover by the new administration. Consolidate power and create a new unaccountable function with authoritarian power. https://apple.news/AWz3nc3_7Sf60dbiumPjyuw
1 · Reply
ripztrip
ripztrip Sep. 14 at 1:27 AM
0 · Reply
ripztrip
ripztrip Sep. 14 at 1:24 AM
0 · Reply
TooHot_toTouch
TooHot_toTouch Sep. 14 at 1:13 AM
$CAPR Waking up to AA with Hope3 as confirmatory and $20+ in premarket would be a beautiful sight!
3 · Reply